Novavax Inc NVAX
News
Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe
Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026
Novavax to Participate in September Investor Conferences
FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech, Novavax — Update
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
Novavax Strikes License Deal With Pfizer for Use of Matrix-M Adjuvant

